Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Abstract We conducted an institutional study to compare the clinical and pathological efficacy between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle albumin–bound paclitaxel plus gemcitabine (nab‐P/G) for borderline resectable pancreatic cancer (BRPC) and locally advanced...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wiley 2020-07-01
Cyfres:Cancer Medicine
Pynciau:
chemotherapy
FOLFIRINOX
nab‐paclitaxel
neoadjuvant
pancreatic cancer
radiation
Mynediad Ar-lein:https://doi.org/10.1002/cam4.3075
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg